Sustained remission at long term follow-up in adolescents and young adults with chronic primary immune thrombocytopenia∗

Alexandra Schifferli, Gautier Le Gavrian, Nathalie Aladjidi, Guillaume Moulis, Bertrand Godeau, Thierry Leblanc, Sébastien Héritier, Helder Fernandes, Thomas Kühne · 2024

Read Sustained remission at long term follow-up in adolescents and young adults with chronic primary immune thrombocytopenia∗ by Alexandra Schifferli, Gautier Le Gavrian, Nathalie Aladjidi, Guillaume Moulis, Bertrand Godeau, Thierry Leblanc, Sébastien Héritier, Helder Fernandes, Thomas Kühne (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11696666.txt.

Introduction

Alexandra Schifferli and colleagues follow adolescents and young adults with chronic primary immune thrombocytopenia over the long term. Their 2024 study draws on three registries covering patients aged twelve to twenty-five.

Four hundred twenty-seven patients with chronic disease at one year were included, most of them female. Clinical features gradually improved over time, and fewer patients required treatment at later follow-ups. Second-line drug use rose steadily among those still treated, without changing corticosteroid or immunoglobulin needs. The authors track sustained complete remission off treatment, defined by platelet counts maintained without therapy. The study clarifies a long-term course previously described as unclear.

Catalog record

CREATORAlexandra Schifferli, Gautier Le Gavrian, Nathalie Aladjidi, Guillaume Moulis, Bertrand Godeau, Thierry Leblanc, Sébastien Héritier, Helder Fernandes, Thomas Kühne
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE53 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11696666

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Sustained remission at long term follow-up in adolescents and young adults with chronic primary immune thrombocytopenia∗ Authors: Alexandra Schifferli, Gautier Le Gavrian, Nathalie Aladjidi, Guillaume Moulis, Bertrand Godeau, Thierry Leblanc, Sébastien Héritier, Helder Fernandes, Thomas Kühne Published: 2024 ABSTRACT Key Points•At 24-, 36-, and 48-month FU, 10% of AYAs with chronic ITP attain yearly SCROT.•Higher platelet counts and lower use of rescue therapy during the first year of the disease might be predictors of SCROT beyond 12 months. Introduction Immune thrombocytopenia (ITP) exhibits age-dependent clinical characteristics, resulting in different management approaches in children and adults. However, defining ITP in 2 age categories only, children and adults, appears inappropriate because such a definition ignores the clinical characteristics and needs of adolescents and young adults (AYAs). AYAs are underrepresented in practice guidelines, and recommendations are biased by studies and publications focused either on adults with a mean age of >50 years or children with a mean age of <10 years.1,2 This gap can be partially explained by the 2 peaks of incidence: in children aged 1 to 5 years and adults aged >60 years,3 as well as by medical facilities (pediatric and adult hospitals) operating independently and rarely prioritizing the transitional age group. Undoubtedly, health-related quality of life is of particular interest in AYAs displaying an active and changeful life.4 Risk of chronic disease, physical activity limitation, fatigue, bleeding symptoms, and medical management have major effects on the mental health, social life, and professional goals of AYAs. Moreover, drug compliance and side effects may be challenging in this age group.5 Our previous study revealed that up to 2 of 3 AYAs requiring ITP therapy were exposed to corticosteroids, even at the 12-month follow-up (FU).6 Side effects of corticosteroids include mood disorders, muscle weakness, osteopenia, and body changes, such as weight gain, gynecomastia, acne, and hirsutism. These symptoms may have tremendous effects on AYAs.7 In 2019, the international consensus report on the investigation and management of primary ITP cautioned against a common mistake in ITP management: the excessive use of corticosteroids.5 Therefore, minimizing corticosteroid use and avoiding or delaying toxic treatments, such as splenectomy, must be part of the treatment strategy for AYAs with persistent or chronic ITP.8 In our previous publication on AYAs with newly diagnosed ITP,6 we emphasized the high risk of chronicity at 12 months (50%), consistent with the well-known heightened risk in children aged >10 years,2,9, 10, 11, 12 thereby positioning AYAs between adults (70% prevalence of chronic disease) and children (20%). However, patients with initial severe thrombocytopenia receiving frontline treatment had a significant higher remission rate at 1 year than those initially managed with a watch-and-wait approach.6 Little is known about the course of chronic ITP in AYAs. In children with chronic ITP, age >10 years at ITP diagnosis and female sex negatively affect the long-term outcome in terms of bleeding severity, treatment escalation, and progression to secondary ITP.13 However, predictors of sustained complete remission off treatment (SCROT) after 12 months remain unclear. Studying the disease evolution of ITP in AYAs could help to better predict outcomes and to design age-adapted therapies. Through an international collaboration of hematologists and by integrating 3 data sources, we aimed to describe clinical and laboratory data of AYAs with chronic primary ITP up to the 48-month FU. Methods Data sources For this analysis, we extracted data of AYAs from the Pediatric and Adult Registry on Chronic ITP (PARC-ITP) by the Intercontinental Cooperative ITP Study Group from May 2004 to May 2021; the French national prospective OBS’CEREVANCE cohort, covering children (aged <18 years) with autoimmune cytopenia from 2004 to November 2021; and the Cytopénies Auto-immunes Registre Midi-Pyrénéen-France (CARMEN-France), which enrolls adults aged >18 years, from January 2013 to May 2021. Missing FU data were completed until April 2022. The local review boards and national or regional ethical committees approved data extraction from the 3 registries. Informed consent was obtained from all participants in the PARC-ITP and OBS’CEREVANCE cohorts, whereas all patients included in the CARMEN-France registry were informed and did not oppose data collection. Further information regarding the registries is provided in the supplemental Data. Study population We enrolled individuals diagnosed with ITP between the ages of 12 and 25 years, subsequently diagnosed with primary chronic ITP at 12 months. Chronic disease was defined as platelet count of <100 × 109/L or ongoing treatment at 12 months or documented relapse until 48 months (supplement Table 1). Primary ITP was defined according to the criteria set by the international working group,8 indicating isolated thrombocytopenia without the presence of secondary causes, as outlined in supplemental Table 2. Patients with a revised diagnosis of secondary ITP after 12 months were not excluded. Those patients presenting some immunopathological manifestations but without a concluding cause of secondary ITP were classified as primary. Pregnant women at ITP diagnosis and patients misdiagnosed with ITP were excluded, irrespective of timing. Outcomes and definitions This study aims to clinically describe AYAs with chronic primary ITP until 48 months FU and explore secondary ITP causes in patients initially diagnosed as primary. Alongside the age and sex of the cohort, the following parameters were analyzed at initial diagnosis and at the 6-, 12-, 24-, 36-, and 48-month FU periods: platelet count (unique value at FU), presence of bleeding (yes/no), bleeding site, and treatment between 2 FU periods. Any FU visit at 3 to 9 months was designated as the 6-month FU visit. In analogy, any FU visits at 11 to 18, 20 to 30, 32 to 42, and 44 to 54 months were designated as 12-, 24-, 36- and 48-month FU visits, respectively. If multiple FU visits occurred within these ranges, the nearest 1 was considered. When the platelet count was documented as “normal,” the value 150 × 109/L was used. Bleeding was defined as any hemorrhagic event, regardless of bleeding intensity, extent, and frequency, and may have been self-reported or assessed at any clinical examination. Initial therapy was defined as ITP treatment initiated within 1 week of diagnosis. If treatment was initiated later, it was documented in the subsequent FU. Initial treatment lasting >4 weeks was documented as both initial treatment and subsequent 6 months FU treatment. IV immunoglobulin, including anti-D immunoglobulin, and corticosteroids were classified as first-line and/or rescue drugs. Rituximab, thrombopoietin-receptor agonists (TPO-RAs), splenectomy, hydroxychloroquine, and all other immunosuppressive drugs were defined as second-line drugs. Certain ITP drugs were not specifically identified in the questionnaire of PARC-ITP but were listed as “second-line drugs: other,” including dapsone, hydroxychloroquine, belimumab, fostamatinib, and some investigational drugs. The reported number of patients treated with hydroxychloroquine encompasses only patients of CARMEN and OBS'CEREVANCE and is therefore underestimated in our results section. The final outcome was the percentage of AYAs with chronic primary ITP entering SCROT, along with the identification of potential factors associated with SCROT. SCROT was evaluated annually starting at 24 months, defined as a platelet count of ≥100 × 109/L without treatment in the preceding year and no documented relapse in subsequent FU. Relapses after 48 months were not evaluated. Patients entering SCROT between 12 and 36 months were classified as “late SCROT” and between 36 and 48 months as “very late SCROT.” Patients who received splenectomy after 12 months, with sustained platelet counts

Read the complete text